Thank you for being a valued subscriber to NeurologyLive. Click to enter to win an Apple Watch.
In October 2019, the FDA approved Eli Lilly's lasmiditan, marketed as Reyvow, for the acute treatment of migraine with or without aura in adults. The drug is the first approved from a new class of serotonin (5-HT)1F receptor agonists.
This downloadable PDF serves as a convenient, consolidated prescribing guide to help you incorporate this new migraine therapy into your clinical practice.
This downloadable PDF provides you with the most recent updates to key clinical guidelines for the treatment of various neurologic disorders. The guide includes new and updated guideline recommendations from US-, Canadian-, and European-based organizations on management of tic disorders, ischemic stroke, Parkinson disease, pediatric migraine, trigeminal neuralgia, and more.
This eBook takes an in-depth look into the NeurologyLive® clinical focus coverage across a variety of media platforms. This resource covers breaking news, interviews with top experts and coverage of FDA approvals.
NeurologyLive® delivers quality and relevant information to healthcare professionals treating neurological diseases to help them achieve the best patient care possible. We offer an in-depth look at the most up-to-date clinical trial results, FDA approvals, practice-changing research, and expert insight. Through a unique mix of video editorial, like the Peer Exchange platform, NeurologyLive® offers dynamic discussions with authoritative insights, opinions, and perspectives on critical issues facing today's healthcare professionals.